Matthew Barcus
Stock Analyst at Chardan Capital
(2.32)
# 2,569
Out of 4,945 analysts
21
Total ratings
25%
Success rate
19.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $1.72 | +481.40% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $15.78 | +71.10% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.70 | +896.16% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $15.20 | +110.53% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $2.34 | +9,321.84% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.95 | +205.08% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $9.94 | -19.52% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $1.72
Upside: +481.40%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $15.78
Upside: +71.10%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.70
Upside: +896.16%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $15.20
Upside: +110.53%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $2.34
Upside: +9,321.84%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.95
Upside: +205.08%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $9.94
Upside: -19.52%